These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 1553167)
21. An evaluation of CA 549, a circulating marker of breast cancer using a procedure for comparison with CA 15.3. Cazin JL; Gosselin P; Boniface B; Demaille MC; Demaille A Anticancer Res; 1992; 12(3):719-24. PubMed ID: 1622129 [TBL] [Abstract][Full Text] [Related]
22. Anthropometry and the risk of epithelial ovarian cancer. Greer JB; Modugno F; Ness RB; Allen GO Cancer; 2006 May; 106(10):2247-57. PubMed ID: 16596653 [TBL] [Abstract][Full Text] [Related]
23. [The CA-125 tumor marker in epithelial ovarian cancers of stage I]. Nagele F; Vavra N; Kurz C; Sevelda P Wien Klin Wochenschr; 1993; 105(20):585-8. PubMed ID: 8259686 [TBL] [Abstract][Full Text] [Related]
24. Coronary heart disease risk factors and menopause: a study in 1980 Tehranian women, the Tehran Lipid and Glucose Study. Azizi F; Ainy E Climacteric; 2003 Dec; 6(4):330-6. PubMed ID: 15006254 [TBL] [Abstract][Full Text] [Related]
25. Prospective study of serum CA-125 levels as markers of ovarian cancer. Helzlsouer KJ; Bush TL; Alberg AJ; Bass KM; Zacur H; Comstock GW JAMA; 1993 Mar; 269(9):1123-6. PubMed ID: 8433467 [TBL] [Abstract][Full Text] [Related]
26. Factors influencing serum CA125II levels in healthy postmenopausal women. Pauler DK; Menon U; McIntosh M; Symecko HL; Skates SJ; Jacobs IJ Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):489-93. PubMed ID: 11352859 [TBL] [Abstract][Full Text] [Related]
28. Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values. Bon GG; Kenemans P; Verstraeten R; van Kamp GJ; Hilgers J Am J Obstet Gynecol; 1996 Jan; 174(1 Pt 1):107-14. PubMed ID: 8571992 [TBL] [Abstract][Full Text] [Related]
29. CA-125 as a screening test for ovarian cancer. Gocze PM; Freeman DA JAMA; 1993 Jun 23-30; 269(24):3106-7. PubMed ID: 8505808 [No Abstract] [Full Text] [Related]
30. Tumor marker CA 125 level and ovarian volume at different cycle day periods and in postmenopause. Granberg S; Wikland M; Friberg LG Int J Gynaecol Obstet; 1990 Oct; 33(2):149-52. PubMed ID: 1976548 [TBL] [Abstract][Full Text] [Related]
31. [Studies on the use of CA-125 in gynecologic mass screening]. Nakatani K; Hoshiai H; Wada Y; Yajima A Nihon Sanka Fujinka Gakkai Zasshi; 1987 Jan; 39(1):157-60. PubMed ID: 3469285 [No Abstract] [Full Text] [Related]
32. Ovarian cancer screening: new trial tries new twists. McNeil C J Natl Cancer Inst; 1995 Sep; 87(17):1283-5. PubMed ID: 7658479 [No Abstract] [Full Text] [Related]
33. Quantifying the potential benefit of CA 125 screening for ovarian cancer. Skates SJ; Singer DE J Clin Epidemiol; 1991; 44(4-5):365-80. PubMed ID: 2010780 [TBL] [Abstract][Full Text] [Related]
34. CA 125 levels in patients with hypoestrogenic ovarian failure. Bösze P; Kovács Z; Artner A; László J Gynecol Obstet Invest; 1990; 29(1):56-8. PubMed ID: 2351335 [TBL] [Abstract][Full Text] [Related]
35. Screening for ovarian cancer. Still controversial, but encouraging. Wald N; Parkes C BMJ; 1993 Jun; 306(6893):1684. PubMed ID: 8324444 [No Abstract] [Full Text] [Related]
36. Screening for ovarian cancer. Multiple markers may outperform CA 125 alone. Bast R; Woolas R BMJ; 1993 Jun; 306(6893):1684-5. PubMed ID: 8324445 [No Abstract] [Full Text] [Related]
39. The value of CA 125 serum assay in the management of ovarian cancer. Commentary. Jacobs I; Oram D Br J Obstet Gynaecol; 1987 Aug; 94(8):819-21. PubMed ID: 3478081 [No Abstract] [Full Text] [Related]
40. Screening for ovarian cancer. Powell MA J Am Acad Nurse Pract; 1992; 4(1):36-7. PubMed ID: 1605991 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]